Corpus ID: 69142365

Actualidades en terapia hormonal estrogénica y osteoporosis posmenopáusica

@inproceedings{Mrquez2005ActualidadesET,
  title={Actualidades en terapia hormonal estrog{\'e}nica y osteoporosis posmenop{\'a}usica},
  author={V{\'i}ctor Claudio Rivera M{\'a}rquez and Jos{\'e} Halabe Cherem},
  year={2005}
}
Osteoporosis is defined as a generalized skeletal disorder characterized by a reduced bone mass and deterioration of bone tissue quality, with subsequent increased bone fragility and a higher risk of fracture. Postmenopausal osteoporosis occurs in a subgroup of 5175 years old women and is characterized by accelerated and disproportioned loss of trabecular bone. This article reviews hormone replacement therapy as treatment of postmenopausal osteoporosis, as well as other options of treatment. 
2 Citations
Factores de riesgo para alteraciones de la densidad mineral ósea en mujeres posmenopáusicas
TLDR
Determinar los factores de riesgo para presentar alteraciones de la densidad mineral osea en mujeres posmenopausicas atendidas en la consulta de Menopausia y Climaterio de the Maternidad “Dr. Armando Castillo Plaza”, de Maracaibo, Venezuela resultaron ser factores significativamente asociados al diagnostico de osteoporosis u osteopenia. Expand

References

SHOWING 1-10 OF 52 REFERENCES
Treatment of postmenopausal osteoporosis.
  • R. Eastell
  • Medicine
  • The New England journal of medicine
  • 1998
TLDR
The purpose of this review is to consider the evidence that treatments for postmenopausal osteoporosis are effective and safe. Expand
Role of estrogens in the management of postmenopausal bone loss.
  • J. Gallagher
  • Medicine
  • Rheumatic diseases clinics of North America
  • 2001
TLDR
There is now evidence that lower doses of estrogens in elderly women may prevent bone loss while minimizing the side effects seen with higher doses of estrogen, and when adequate calcium, vitamin D, and exercise are used in combination with estrogen-based treatments, more positive increases occur in bone density. Expand
Bone mineral density--clinical use and application.
  • P. Miller
  • Medicine
  • Endocrinology and metabolism clinics of North America
  • 2003
TLDR
With bone densitometry, it is possible for clinicians to diagnose osteoporosis before the first fracture has occurred, predict risk for fracture in men, postmenopausal women, and in patients receiving glucocorticoids. Expand
Parathyroid hormone for treatment of osteoporosis.
TLDR
Parathyroid hormone decreases vertebral fractures and increases spinal bone density in postmenopausal osteoporosis and glucocorticoid-induced osteop orosis, but at the expense of a decrease in radius bone density. Expand
Bone health and aging: implications for menopause.
TLDR
Because lower than usual doses of estrogen have been shown to reduce menopausal symptoms and to protect bone, additional research will likely expand physicians' current knowledge of the use of HT in menopausal women. Expand
Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.
TLDR
The data suggest that risedronate therapy is effective and well tolerated in the treatment of women with established postmenopausal osteoporosis. Expand
Pathogenesis of osteoporosis
TLDR
This chapter reviews the role of these factors in the earlier gain and later loss of bone mass, as well as the cellular mechanisms responsible for the latter, as a prerequisite to the relationship between bone mass and fracture risk in older individuals. Expand
Risedronate prevents new vertebral fractures in postmenopausal women at high risk.
TLDR
Significant reduction in fracture risk after 1 yr is an important benefit in patients at high risk for fracture because, without treatment, these patients are likely to sustain new fractures in the near term. Expand
The role of estrogen in the prevention of osteoporosis.
  • R. Lindsay
  • Medicine
  • Endocrinology and metabolism clinics of North America
  • 1998
TLDR
The role and pathophysiology of estrogen in bone remodeling is reviewed as well as aspects such as dose versus response, route of administration, and interactions with other agents. Expand
Timing of postmenopausal estrogen for optimal bone mineral density. The Rancho Bernardo Study.
TLDR
Estrogen initiated in the menopausal period and continued into late life is associated with the highest bone density, and estrogen begun after age 60 years and continued appears to offer nearly equal bone-conserving benefit. Expand
...
1
2
3
4
5
...